For research and educational purposes only. Not intended for human consumption.
FOXO4-DRI
Limited Research- •11.73x selectivity for senescent cells confirmed
- •Mouse longevity restoration data published
- •FOXO4-p53 disruption mechanism detailed
Senolytic Peptide | FOXO4-p53 Disruption for Cellular Aging Research
Overview
What is FOXO4-DRI?
FOXO4-DRI (FOXO4-D-Retro-Inverso) is a synthetic 46-amino acid peptide designed to selectively eliminate senescent cells - damaged cells that accumulate with age and secrete harmful inflammatory factors (SASP). The peptide uses D-amino acids in reversed sequence, making it resistant to proteolytic degradation while maintaining binding function. It shows 11.73-fold selectivity for senescent over healthy cells.
Key Benefits
Selective senescent cell elimination, tissue homeostasis restoration, potential anti-aging effects. Mouse studies showed restored fur density, renal function, and physical fitness.
Mechanism of Action
Disrupts FOXO4-p53 interaction in senescent cells, causing p53 nuclear exclusion. Free p53 translocates to mitochondria, triggering caspase-dependent apoptosis specifically in senescent cells while sparing healthy cells (11.73-fold selectivity demonstrated).
Molecular Information
Pharmacokinetics
Research Indications
Senescent Cell Clearance
Selectively eliminates 'zombie' senescent cells that accumulate with age and secrete harmful inflammatory factors (SASP).
Tissue Homeostasis
Mouse studies show restoration of tissue function including fur regrowth, renal function, and physical fitness.
Rejuvenation
Potential to restore youthful tissue function by removing accumulated senescent cells.
Research Protocols
Disclaimer: CRITICAL: FOXO4-DRI is a research compound with NO human clinical data. Dosing protocols are translated from mouse studies or derived from anecdotal self-experimentation. Human pharmacokinetics, optimal dosing, and long-term safety are completely unknown. This peptide targets the p53 tumor suppressor pathway - proceed only with full understanding of experimental nature.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Mouse Research Protocol (IV) | 5 mg/kg | Every other day × 3 doses | IV |
| Mouse Research Protocol (IP) | 5 mg/kg | Every other day × 3 doses | IP |
| Anecdotal Human Translation | ~25 mg per injection | Every other day × 3 doses (75-100 mg total per cycle) | SubQ |
Timing: Cellular uptake within 2-4 hours, detectable for 72+ hours. D-amino acid structure provides protease resistance.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Store lyophilized powder at -20°C until use
Allow vial to reach room temperature before reconstitution
Add sterile water slowly down vial side
Gently swirl until dissolved - do not shake (protein may denature)
Solution should be clear; discard if cloudy or precipitated
Use reconstituted solution within 7-10 days
Store reconstituted at 2-8°C
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
No Human Clinical Trials
All data from mouse studies and cell culture. Human pharmacokinetics, safety, and efficacy unknown.
p53 Pathway Involvement
p53 is a critical tumor suppressor. Long-term effects of repeated FOXO4-p53 modulation unknown.
High Synthesis Cost
46 D-amino acids make production expensive. Risk of low-quality or counterfeit products.
High Selectivity Demonstrated
11.73-fold selectivity for senescent vs healthy cells in original research.
Third-Party Testing Essential
Due to complex D-amino acid synthesis, verify peptide identity and purity via independent testing.
Avoid with Rapamycin/Quercetin
May diminish senolytic effects. Require 1-2 week washout period.
What to Expect
- •Week 1: No reliable human timeline established
- •Mouse studies: Improvements seen within 1-4 weeks
- •Fur density restored in aged mice within 2-3 weeks
- •Renal function normalized within study period (weeks)
- •Human effects poorly characterized; proceed with caution
Side Effects & Safety
Side Effects
- •CRITICAL: No human clinical trials - all safety data from animal studies
- •Original mouse studies showed no thrombocytopenia (unlike ABT-737)
- •No cardiac abnormalities on histology in mouse studies
- •Does not sensitize healthy cells to DNA damage
- •Anecdotal: Burning/itching at injection site reported
- •Avoid concurrent use with Rapamycin, Quercetin, corticosteroids
- •May not be useful for healthy individuals under 40 with low senescent cell burden
- •Theoretical concern: p53 pathway critical for tumor suppression
- •Unknown immunogenicity with repeated dosing
When to Stop
- •Signs of unexpected immune reaction
- •Severe injection site reactions
- •Any signs of abnormal cell growth
- •Persistent fatigue or weakness
- •Consult healthcare provider immediately
References
3 StudiesTargeted Apoptosis of Senescent Cells (2017)
Mouse | 5 mg/kg IV | 3 doses every other day | 11.73-fold selectivity for senescent cells
Landmark study introducing FOXO4-DRI. In aged mice, restored fur density, normalized renal function, increased voluntary running activity, and protected against doxorubicin-induced liver damage.
View StudyAge-Related Testosterone Insufficiency (2020)
Mouse | 5 mg/kg IP | Every other day × 3 | Increased serum testosterone
Treatment significantly increased serum testosterone levels in aged mice. Enhanced expression of testosterone synthesis enzymes. Decreased testicular senescence markers.
Senolytic Effect on Human Chondrocytes (2021)
Human cells in vitro | Passaged chondrocytes | Removed over 50% senescent cells
Removed over 50% of highly-passaged senescent chondrocytes while not affecting minimally-passaged cells. Reduced senescence markers and improved cartilage quality.
Quick Start Guide
Research Disclaimer
FOXO4-DRI is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving FOXO4-DRI must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of FOXO4-DRI for any purpose. Consult qualified professionals for any research applications.